

Eisai aims for novel drug discovery for neurodegenerative disorders

17 March 2021 | News

Enters into research collaboration with DZNE in Germany



German firm Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) and Japan based Eisai have announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells.

DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.

The collaboration will incorporate DZNE's expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.

Dr. Teiji Kimura, Vice President, Chief Discovery Officer of the Eisai Neurology Business Group, commented: "Neurodegenerative diseases including AD comprise a disease area with high unmet medical needs. DZNE has many world-leading scientists in this field and we expect to create new disease-modifying therapies for those suffering from neurodegenerative disorders by conducting research for immune and metabolic incompetence in neurons and glia cells."